Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
申请人:Boléa Christelle
公开号:US20120122907A1
公开(公告)日:2012-05-17
The present invention relates to novel compounds of Formula (I), wherein M, P, X
1
, (A)
m
and (B)
n
are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
[EN] IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF<br/>[FR] COMPOSÉS IMIDAZOLE SERVANT DE MODULATEURS DES RÉCEPTEURS DE LA FSHR ET LEURS UTILISATIONS
申请人:MERCK PATENT GMBH
公开号:WO2014209978A1
公开(公告)日:2014-12-31
The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
申请人:Boléa Christelle
公开号:US20100144756A1
公开(公告)日:2010-06-10
The present invention relates to novel compounds of Formula (I), wherein X
1
, X
2
, X
3
, X
4
, Y
1
, Y
2
, Y
3
, Y
4
, M
1
, M
2
, M
3
, A
m
and B
n
are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors.
The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.